Literature DB >> 10843884

Metabolism of VLDL is increased in streptozotocin-induced diabetic rat hearts.

N Sambandam1, M A Abrahani, S Craig, O Al-Atar, E Jeon, B Rodrigues.   

Abstract

In streptozotocin (STZ)-induced diabetic rats, we previously showed an increased heparin-releasable (luminal) lipoprotein lipase (LPL) activity from perfused hearts. To study the effect of this enlarged LPL pool on triglyceride (TG)-rich lipoproteins, we examined the metabolism of very-low-density lipoprotein (VLDL) perfused through control and diabetic hearts. Diabetic rats had elevated TG levels compared with control. However, fasting for 16 h abolished this difference. When the plasma lipoprotein fraction of density <1.006 g/ml from fasted control and diabetic rats was incubated in vitro with purified bovine or rat LPL, VLDL from diabetic animals was hydrolyzed as proficiently as VLDL from control animals. Post-heparin plasma lipolytic activity was comparable in control and diabetic animals. However, perfusion of control and diabetic rats with heparinase indicated that diabetic hearts had larger amounts of LPL bound to heparan sulfate proteoglycan-binding sites. [(3)H]VLDL obtained from control rats, when recirculated through the isolated heart, disappeared at a significantly faster rate from diabetic than from control rat hearts. This increased VLDL-TG hydrolysis was essentially abolished by prior perfusion of the diabetic heart with heparin, implicating LPL in this process. These findings suggest that the enlarged LPL pool in the diabetic heart is present at a functionally relevant location (at the capillary lumen) and is capable of hydrolyzing VLDL. This could increase the delivery of free fatty acid to the heart, and the resultant metabolic changes could induce the subsequent cardiomyopathy that is observed in the chronic diabetic rat.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843884     DOI: 10.1152/ajpheart.2000.278.6.H1874

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  8 in total

Review 1.  Metabolic cardiomyopathies.

Authors:  B Guertl; C Noehammer; G Hoefler
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

2.  Hypolipidemic activity of Semecarpus anacardium in Streptozotocin induced diabetic rats.

Authors:  Aseervatham Jaya; Palanivelu Shanthi; Panchanatham Sachdanandam
Journal:  Endocrine       Date:  2010-06-24       Impact factor: 3.633

Review 3.  Cardiac lipotoxicity: molecular pathways and therapeutic implications.

Authors:  Konstantinos Drosatos; P Christian Schulze
Journal:  Curr Heart Fail Rep       Date:  2013-06

4.  Utilization of triacylglycerol-rich lipoproteins by the working rat heart: routes of uptake and metabolic fates.

Authors:  You-Guo Niu; David Hauton; Rhys D Evans
Journal:  J Physiol       Date:  2004-04-30       Impact factor: 5.182

5.  Very-low-density lipoprotein: complex particles in cardiac energy metabolism.

Authors:  You-Guo Niu; Rhys D Evans
Journal:  J Lipids       Date:  2011-07-03

6.  Differential effects of angiopoietin-like 4 in brain and muscle on regulation of lipoprotein lipase activity.

Authors:  Sara Gry Vienberg; André Kleinridders; Ryo Suzuki; C Ronald Kahn
Journal:  Mol Metab       Date:  2014-11-13       Impact factor: 7.422

7.  Cleavage of protein kinase D after acute hypoinsulinemia prevents excessive lipoprotein lipase-mediated cardiac triglyceride accumulation.

Authors:  Min Suk Kim; Fang Wang; Prasanth Puthanveetil; Girish Kewalramani; Sheila Innis; Lucy Marzban; Susan F Steinberg; Travis D Webber; Timothy J Kieffer; Ashraf Abrahani; Brian Rodrigues
Journal:  Diabetes       Date:  2009-11       Impact factor: 9.461

8.  Diabetes Mellitus Severity and a Switch From Using Lipoprotein Lipase to Adipose-Derived Fatty Acid Results in a Cardiac Metabolic Signature That Embraces Cell Death.

Authors:  Karanjit Puri; Nathaniel Lal; Rui Shang; Sanjoy Ghosh; Stephane Flibotte; Roger Dyer; Bahira Hussein; Brian Rodrigues
Journal:  J Am Heart Assoc       Date:  2019-10-31       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.